PLoS ONE · 2013 · 82 citations · 35 references
Life SciencesImmunologyNeurologyAutoimmunityImmunopathologyNeuroimmunologyCerebrospinal Fluid ImmunologyDemyelinating DiseasesDemyelinating DisordersAntibodiesCerebrospinal Fluid ImmunophenotypingDemyelinating Disease AssessmentDisease Progression PredictionDisease Progression StagingImmune-mediated DemyelinationMulti-center Trials
OBJECTIVES: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. RESULTS: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. CONCLUSIONS: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
35
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text
Medicine, Neurology, Neuroscience +10
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer, Maria Ban, Anu Kemppinen et al. · Nature · 2011 · 2.7K citations · Full text
Life Sciences, Immunology, Neurology +17
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Stephen M. Smith, Yongyue Zhang, Mark Jenkinson et al. · NeuroImage · 2002 · 2.1K citations
its Panel on Folate, Other B Vitamins · 1998 · 964 citations